The primary therapeutic role of Cefmetazon provides supportive therapeutic benefit in addressing bacterial infections. It is considered relevant in clinical scenarios where supportive symptom management is appropriate and addresses heightened systemic burden.

Comprehensive Symptom and Condition Relief

This medication is applied in conditions marked by increased physiological stress stemming from severe infections. These include complicated urinary tract infections (such as pyelonephritis), pneumonia and other severe respiratory infections, intra-abdominal or gynaecological infections, and managing bloodborne infection (bacteremia). The drug is used for managing symptom clusters that may become intense or disruptive, such as persistent high fever and intense, localized pain or tenderness. Cefmetazon provides support that helps ease the overall symptom burden as it addresses the infectious process.

“This medication is relevant in contexts where short-term symptomatic assistance is needed in situations involving certain distressing symptoms.”

It is also applied in situations where symptoms are driven by antibiotic-resistant organisms, such as those that are known to be drug-resistant. The use of Cefmetazon contributes to improved comfort during these periods and assists with maintaining functional stability. Furthermore, it is commonly used as surgical prophylaxis—a preventative measure—before clean-contaminated procedures like colorectal surgery and hysterectomy, which supports general well-being during the recovery phase.

---

Quick Fact: Relevant for Symptoms Related to Systemic Imbalance

Regulatory References

1. Japanese Drug Information Sheet on Cefmetazole

Who Can and Cannot Use Cefmetazon?

This section defines population eligibility for Cefmetazon based strictly on official governmental regulatory documents.

Eligibility Scope

Classification	Status	Affected Population
Contraindicated	Prohibited Use	Patients with a known hypersensitivity to Cefmetazole or the cephalosporin class of antibiotics.
Conditional Use	Use Restricted	Patients with impaired renal function (kidney dysfunction).
Not Established	Not Recommended	Pediatric patients (under 18 years of age).

Age- and Condition-Specific Eligibility Rules

Populations Allowed The medicine is permitted for use in adults for labeled infections and surgical prophylaxis. Older adults may use the medicine but should be monitored due to the higher likelihood of decreased kidney function.

Populations with Restrictions Use is contraindicated in those with documented allergies to Cefmetazole or cephalosporins, and caution is also advised for patients with a history of severe penicillin allergy. Furthermore, patients with renal impairment require an adjustment to the dose as mandated by official labeling. Caution is also required for individuals with a history of colitis, seizure disorders, or coagulation issues.

Pregnancy and Lactation Use during pregnancy is restricted to cases where the need is clearly established. For lactation (breastfeeding), use is not generally recommended as the drug is excreted in human milk, defining conditional eligibility limits for these groups.

Interactions with other medicines and products

Cefmetazon's regulatory interaction profile is primarily defined by pharmacokinetic competition in the kidney and specific additive pharmacodynamic effects that restrict certain co-administrations.

Pharmacokinetic Interactions

Co-administration with Probenecid results in a clinically relevant pharmacokinetic interaction. This substance, which is a renal organic anion transporter inhibitor, causes a reduction in the renal tubular secretion of Cefmetazon. The outcome of this interaction is a documented increase and prolongation of the Cefmetazon plasma concentration and systemic exposure (AUC/Cmax).

Pharmacodynamic Interactions and Restrictions

Use with Vitamin K Antagonists (e.g., Warfarin) is associated with an increased risk of bleeding or hemorrhage due to the potential for Cefmetazon to affect prothrombin activity. An additive nephrotoxicity risk is also officially noted when Cefmetazon is administered concomitantly with Aminoglycoside Antibiotics (e.g., Tobramycin, Amikacin) or Potent Diuretics (e.g., Furosemide).

Alcohol and Procedural Constraints

A mandatory restriction applies to alcohol (Ethanol) consumption. The official labeling specifies that co-ingestion may precipitate an acute disulfiram-like reaction; avoidance is required during treatment and for a documented period of at least 7 days following the final dose. Furthermore, the drug is documented to cause potential false-positive results when copper reduction reagents are used for urine glucose analysis. The interaction profile notes that patients with Renal Impairment may face a heightened risk of accumulation and interaction severity.

Inhibiting the Peptidoglycan Cross-Linking Cascade

Cefmetazon, a cephamycin antibiotic, exerts its action by directly targeting and binding to Penicillin-Binding Proteins (PBPs) within the bacterial cell membrane. These PBPs are critical enzymes (transpeptidases) responsible for the final cross-linking step in the construction of the bacterial peptidoglycan cell wall. The binding of Cefmetazon to PBPs irreversibly blocks the necessary cross-linking, preventing the bacteria from forming a structurally sound, rigid outer wall.

---

Disrupting Bacterial Cell Wall Integrity

This structural failure leads to the activation of bacterial autolytic enzymes, causing the bacteria to rupture (lysis) due to high internal osmotic pressure, which results in the destruction of the bacterial cell. Additionally, Cefmetazon possesses inherent chemical stability, which makes it highly resistant to inactivation by certain beta-lactamase enzymes produced by bacteria. This structural stability allows the drug to maintain functional activity at the bacterial PBP targets, leading to continued cell wall inhibition despite the presence of the enzyme.

How Cefmetazon is Used

Cefmetazon (Cefmetazole) is administered exclusively by the parenteral route, which means it is given directly into the body, typically through intravenous (IV) injection or infusion. As it is supplied as a sterile powder for injection, the dose must be reconstituted with an appropriate aqueous solvent, such as 0.9% Sodium Chloride or Sterile Water for Injection, prior to use.

Administration and Dosage Schedules

Dosing and scheduling patterns are established for clinical use. For treating established bacterial infections, the standard adult dose is generally 1 g to 2 g administered intravenously, typically repeated every 12 hours. The maximum labeled dose for severe infections can be up to 4 g daily, which is divided into multiple administrations.

For surgical prophylaxis, a 2 g IV dose is administered as a single use 30 to 90 minutes before the surgical incision. Alternatively, a multi-dose regimen may be employed, starting with a 1 g IV dose before surgery and repeating it at 8 and 16 hours afterward. IV doses are administered either as a slow push over 3 to 5 minutes or as an infusion over a longer period, such as 10 to 60 minutes.

Population-Specific Use Adjustments

Precise interval adjustments are required for patients with impaired renal function based on their Creatinine Clearance (CrCl). For instance, the administration interval must be extended from the standard every 12 hours to every 48 hours for patients with a CrCl below 10 mL/min. Furthermore, patients undergoing hemodialysis must receive the dose after the dialysis session is completed.

Research evidence / Overview of studies for Cefmetazon

Research has primarily evaluated Cefmetazon in the context of preventing infections during surgery and for treating specific established bacterial infections. The available evidence, which includes various comparative studies and Randomized Controlled Trials (RCTs), helps contextualize how Cefmetazon was observed in specific research conditions.

---

Evidence for Surgical Prophylaxis (Colorectal and Biliary Procedures)

Research has explored Cefmetazon in the setting of surgical prophylaxis, which means preventing infection before certain types of surgery. For patients undergoing elective colorectal surgery, studies were evaluated in order to assess how different Cefmetazon dosing and combination approaches relate to the prevention of post-operative complications. Researchers utilized RCTs that examined specific outcomes related to systemic or functional imbalance, including the rate of surgical site infection (SSI), both near the skin incision and deeper within the body.

Studies monitored these infection rates for defined time intervals, generally within the 30 days following the operation. Studies monitored patterns observed when Cefmetazon was evaluated in a single dose versus multiple doses. Research has also evaluated Cefmetazon in the context of biliary tract surgery, where comparative trials examined outcomes related to infectious complications and monitored factors like the duration of fever.

---

Evidence for Treating Intra-abdominal Infections

Cefmetazon was evaluated in comparative studies for the treatment of established intra-abdominal infections (IAI), which are conditions associated with acute or disruptive episodes. These studies focused on measuring clinical success rates and microbiological outcomes, specifically checking if the targeted bacteria were eliminated.

Studies report how symptoms evolved in the observed populations when Cefmetazon was compared against older or existing antibiotics. The evidence is limited by several factors. Cefmetazon-specific comparative trials may be generally characterized by modest sample sizes. Limited comparative evidence is available against newer broad-spectrum antibiotics, indicating that data are still emerging in this research context.

Key Studies & References

1. Japanese Drug Information Sheet on Cefmetazole

Common questions about Cefmetazon (FAQ)

---

Q: Can Cefmetazon cause a metallic taste?

Official documentation for Cefmetazon lists a rare side effect referred to as dysgeusia or taste perversion. This means an altered sense of taste has been reported by some patients, which may occasionally be described as metallic. This effect is a documented, specific side effect, and any unusual change in taste may be discussed with a healthcare provider.

---

Q: Are there any common foods or drinks that should be avoided when using Cefmetazon?

Official labeling includes a restriction on the use of alcohol (Ethanol) during treatment. This restriction continues for a documented period of at least 7 days after the final dose due to the potential risk of a severe disulfiram-like reaction. No other common foods or non-alcoholic drinks are specifically restricted in official regulatory documents.

---

Q: Can Cefmetazon be used in children?

Regulatory documents indicate that use in pediatric patients (those under 18 years of age) is not established and is generally not recommended by official governmental bodies. This is because safety and efficacy in this age group have not been formally established in the official labeling.

---

Q: What is the typical length of time Cefmetazon is used?

The length of time Cefmetazon is used depends on the specific condition being treated. For established infections, treatment durations are described as commonly spanning several days, such as 7 to 14 days. However, for surgical prophylaxis (preventing infection), administration is often limited to a single dose or a very short, multi-dose regimen.

---

Q: Is Cefmetazon considered a broad-spectrum antibiotic?

Cefmetazon is classified as a cephamycin antibiotic and has demonstrated a broad range of activity, similar to second-generation cephalosporins. Regulatory documents indicate it is effective against a variety of bacteria, including Enterobacteriaceae and anaerobic bacteria, and is known for its stability against many bacterial beta-lactamase enzymes.

---

Q: Is Cefmetazon the same as Cefoxitin?

Cefmetazon and Cefoxitin are closely related, as both belong to the cephamycin subclass of cephalosporin antibiotics. While they share similar clinical applications, official information indicates that Cefmetazon may demonstrate a different level of activity than Cefoxitin against certain specific organisms within their shared antibacterial spectrum.

---

Q: Are there any long-term side effects associated with Cefmetazon use?

Official labeling primarily focuses on effects during and shortly after administration, and a specific long-term safety profile for use extending months or years beyond treatment is not defined. The documentation lists adverse events associated with the drug's use during and shortly after administration.

---

Q: What types of bacteria is Cefmetazon active against?

Official product information states that Cefmetazon is active against a range of bacteria, including common disease-causing organisms. This includes bacteria such as Enterobacteriaceae (like E. coli), certain types of Staphylococcus and Streptococcus, Haemophilus spp., and most significantly, many anaerobic bacteria.

---

Q: Does Cefmetazon affect the normal gut flora?

Yes, as an antibacterial medication, its official use is associated with altering the normal balance of bacteria in the colon, known as the gut flora. This change can sometimes lead to the overgrowth of Clostridium difficile (C. difficile), which may result in a condition called pseudomembranous colitis.

---

Q: Can Cefmetazon cause confusion or dizziness?

Rarely, central nervous system effects such as dizziness and confusion have been reported with the use of this drug or drugs in the same class. Official safety notes warn that serious neurologic adverse reactions, including seizures, have been reported, particularly in patients with existing kidney impairment.

---

Q: What research is available on resistance patterns to Cefmetazon?

Official research and microbiology sections highlight that Cefmetazon has excellent stability and improved resistance compared to some older antibiotics. This stability is against certain beta-lactamase enzymes, which are common bacterial defense mechanisms that inactivate beta-lactam drugs.

---

Q: Does Cefmetazon come in an oral pill form?

No. Official information defines Cefmetazon as a sterile powder for injection or intravenous solution. It is administered exclusively by the parenteral route (injection or infusion) and is not supplied in an oral pill form.

---

Q: Can Cefmetazon affect blood sugar levels?

While Cefmetazon itself is not documented to have an actual effect on a person's blood glucose levels, official labeling notes that it can cause potential false-positive results when certain copper reduction reagents are used for urine glucose testing. This is a laboratory interaction, not a physical effect on blood sugar.

---

Q: Is Cefmetazon considered safe for people with liver disease?

Official documentation notes that patients with hepatic impairment (liver disease) should be monitored, as they may be at risk of prolonged prothrombin time (a coagulation issue). While some official guides do not recommend specific dosage adjustments for mild liver disease, the monitoring of these patients is emphasized.

The storage and disposal of Cefmetazon (Cefmetazole Sodium for Injection) are governed by specific regulatory requirements for both the dry powder and the reconstituted solution.

Storage Requirements

Product Form	Temperature / Condition
Unopened Powder	Store at Controlled Room Temperature (15 C to 30 C) and protect from light.
Reconstituted Solution	Must not be frozen. Stability is time-limited: typically mathbf24 hours refrigerated (2 C to 8 C) or mathbf6 hours at room temperature (25 C).

Child-Safety and Disposal

• The medication must be kept out of the sight and reach of children.
• Unused or expired product must be disposed of according to local regulations for pharmaceutical waste.
• It must not be thrown away into wastewater or regular household trash.